A slimmed-down BioMarin started the new year with a bang, hitting the annual J.P. Morgan Healthcare Conference with the goal of tapping its skillset to strike deals that bolster its pipeline of ...
BioMarin’s Q4 adjusted EPS rose to $0.92, surpassing the $0.53 consensus. 2025 sales guidance set at $3.1 billion-$3.2 billion, with EPS expected at $4.20-$4.40. Join Nic Chahine live on ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback